4. Shooting Star Scientific
Make way, Manti Te'o. You have company -- and it's very much real.
Like the Notre Dame linebacker who lied about his fictional girlfriend, Star Scientific (STSI) misled investors about the involvement of Johns Hopkins University in the clinical testing of the company's retail nutritional supplement anatabine. TheStreet's own biotech ax Adam Feuerstein snared the company this Wednesday for fabricating a link between the well-respected school and anatabine, which accounted for a disappointing $1.7 million of Star's sales last quarter.
Star reported initial interim results from a clinical study of anatabine as a potential treatment for thyroid disease on Jan. 7. The company claims the study succeeded, but Feuerstein points out that it failed to disclose any real data. Star's press release included a promotional quote about anatabine from Dr. Paul Ladenson, described as a "senior endocrinological consultant" for the study."Ladeneson's real job is director of the Division of Endocrinology and Metabolism at Johns Hopkins School of Medicine. He's a thyroid disease expert," says Feuerstein. "Why did Star Scientific omit Ladenson's academic affiliation from its Jan. 7 press release? Likely because, as Desmon made clear, Ladenson's role in Star Scientific's anatabine thyroid disease study had nothing to do with Johns Hopkins." So who is the "Desmon" to whom Feuerstein is referring? Is that another imaginary figure? Not in the least. That person is very real, indeed. In fact, she's the person putting the kibosh on Star's silly hype. "The Antabloc Supplementation Autoimmune Prevention [ASAP] clinical study was not conducted at or approved by Johns Hopkins," said Johns Hopkins' spokesperson Stephanie Desmon. "We do have guidelines about such things and he [Ladenson] is in violation here." She added that Johns Hopkins has started an inquiry into the matter. Shares of Star Scientific sank over 10% Wednesday on the heels of Feuerstein's report even as the broader market spiked. Yep, it doesn't get much realer than that.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV